Venture Financing Structural Pitfalls
Venture Financing Structural Pitfalls: Model Your Fundraise
Post-money valuation cap SAFEs are currently the dominant pre-seed and seed financing instrument, with pre-money SAFEs rarely seen in practice today. Because SAFEs defer dilution visibility, founders often don’t realize how much equity they’ve given away until a priced round is imminent.
Stacking SAFEs at different valuations or terms compounds this complexity, making early modeling essential. The ideal time to run the model is before signing a term sheet, while there is still room to negotiate — primarily on valuation and option pool size.
Investors are far more receptive to adjustments at the term sheet stage than after attorneys have begun drafting documents.
Founders should model multiple scenarios (e.g., varying option pool percentages or valuations) to build intuition about downstream dilution effects.
We generally recommend that an external CFO or ECVC counsel review outputs of any automated model, just to avoid human input error on something this consequential.
***
Transcript:
Lindsey S. Mignano:
Let's talk about something that's kind of near and dear to my heart, which is pro forma modeling before the raise. Something that founders, if we're looking prospectively, like what should you do? We've chatted about this before, using your CFO or your law firm to help you with regard to understanding how things are going to convert because we have so many founders today who are utilizing these post-money valuation cap SAFEs. It's the most common instrument.
I haven't seen very many pre-money being negotiated and used anymore these days. So let's talk a little bit about that, just so founders understand if we have been raising a SAFE and we're going through a Series Seed or going to a Series A, what are things that we should be looking forward to in that process?
Ariana Shaffer:
Yeah, definitely. So, I think SAFEs are great is because they're simple, they're easy to understand, they're pretty easy to negotiate because there's not that many terms. But I think one of the things that makes them challenging is it's really hard to know how much dilution you're going to have when you do finally raise money.
And so, like we talked about in a previous video, if you are doing SAFEs, definitely do the modeling at that point just to make sure that if you're stacking SAFEs, meaning you're giving them at different valuations or on different terms, you kind of know how those all convert.
And then also that you can kind of preemptively know what dilution looks like. Obviously, it will be different when you actually get the terms for your Series A, but it's good to do the cap table modeling at the SAFE round, and then again before you sign the term sheet, would be ideal. That way, if there's anything you need to negotiate, you can. And there's a couple levers you can negotiate, right? Obviously you can't negotiate the SAFE terms at that time, but you could negotiate the valuation, you could negotiate the size of the option pool. Those are probably the two biggest levers.
So, if you do the cap table modeling before you sign the term sheet, you have that opportunity to say, "Hey, actually I thought we were going to be closer to here. What are the levers I can pull to make sure that we get there?" And your investors are a lot more likely to hear you out at that point than they are once things are signed and now they've turned it over to the attorneys who are already drafting documents.
So I would say that's the biggest thing. And we obviously do a lot of pro forma modeling, we can help you with that. There are services out there that do them. I'm sure people use AI tools now to do it — my disclaimer would be don't put confidential information into AI. And also, just double-check it because it is, after all, not a human, and even humans make mistakes. So you can bet that AI will make mistakes too.
So that would be my advice: just do the modeling early and do it often, and do different modeling, because I think part of it is just understanding how, if I change my cap table from 5% to 10%, look what it does to dilution. Or if our valuation changes, that affects it down the road in this way.
So I think all of that's just really helpful as a founder to know. It will make you more confident when you're negotiating with your investors and just allow you to have a better view of what's coming and where you stand on your cap table post-financing.
Lindsey S. Mignano
Absolutely. And there's a lot of cap table software that offers pro forma modeling. And while we don't want to ever represent as lawyers that it's completely correct, we do have most of our clients kind of fiddling around in there long before their actual priced round raise.
We recommend either having someone who is not you — your CFO, external CFO, or, if you don't have one, your lawyer helping you out with that.
There are some gotchas that we found looking at various cap table pro forma options, and just having an experienced set of eyes look is really helpful.
Additionally, we've had some great CFOs that we've worked with who will also take into account people who are and are not exercising their pro ratas at that point. So having someone who can help you model that through is really helpful, just so that you have an understanding of where you're going to land.
Venture Financing Structural Pitfalls
The transition from a "handshake" Seed round to a sophisticated Series A is where many founders accidentally sign away their company’s future. Here are the most common mistakes we see, all of which can be prevented by prior conversations with experienced counsel.
Preference Stack: The most lethal mistakes occur in the preference stack. While a 1x liquidation preference is standard, agreeing to "participating preferred" stock allows investors to double-dip — taking their initial investment back plus their pro-rata share of the remaining proceeds—gutting the founder’s payout in a mid-market exit.
Full Ratchet: Anti-dilution scope is another silent killer. While "broad-based weighted average" protection is market-standard, "full-ratchet" clauses can cause catastrophic dilution during a down-round, as they reset the investor's price to the lowest new share price regardless of how much capital was raised.
Scope for Board Consents: Furthermore, overbroad protective provisions can paralyze operations, requiring board consent for minor tasks like hiring mid-level staff or pivoting product features.
Know your SAFEs – Post-Money v. Pre-Money: Founders also frequently stumble on post-money SAFE math. Mistaking a post-money SAFE for a pre-money one leads to "dilution shock," where founders realize too late that the SAFE holders' ownership is locked in, and all dilution from the new option pool falls solely on the founders.
Investor Rights: Granting premature board control (i.e., a Board seat at a SAFE seed round) or aggressive pay-to-play terms—which force early investors to participate in later rounds or lose their rights—can create a toxic cap table that scares off top-tier VCs. In venture finance, the "price" is only half the story; the terms are where the control is won or lost.
Cap Table Modeling Before the Raise: Most of our clients never sign a term sheet without a pro-forma cap table that first models out conversion of existing SAFEs/Notes and a possible "Option Pool Shuffle" with their CFOs of record to account for the pool expansion coming out of the pre-money valuation.